Takeda Pharmaceutical Co., Ltd. (4502)

3,657.0
-66.0(-1.77%)
  • Volume:
    5,994,400
  • Bid/Ask:
    3,656.0/3,659.0
  • Day's Range:
    3,637.0 - 3,668.0

4502 Overview

Prev. Close
3,723
Day's Range
3,637-3,668
Revenue
3.2T
Open
3,660
52 wk Range
3,239-4,365
EPS
239.95
Volume
5,994,400
Market Cap
5.72T
Dividend (Yield)
180.00
(4.92%)
Average Volume (3m)
5,818,773
P/E Ratio
15.24
Beta
1.15
1-Year Change
-9.07%
Shares Outstanding
1,565,348,471
Next Earnings Date
29 Jul 2021
What is your sentiment on Takeda Pharmaceutical Co., Ltd.?
or
Market is currently closed. Voting is open during market hours.

Takeda Pharmaceutical Co., Ltd. News

Takeda Pharmaceutical Co., Ltd. Analysis

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong SellStrong SellSellStrong SellStrong Sell
Technical IndicatorsSellStrong BuyStrong SellStrong SellStrong Sell
SummaryStrong SellStrong SellStrong SellStrong SellStrong Sell

Takeda Pharmaceutical Co., Ltd. Company Profile

Takeda Pharmaceutical Co., Ltd. Company Profile

Employees
47495
Market
Japan

Takeda Pharmaceutical Company Limited engages in the research, development, manufacturing, and marketing of pharmaceutical products, over-the-counter medicines and quasi-drug consumer products, and other healthcare products. It offers pharmaceutical products in the areas of gastroenterology; oncology; neuroscience; and rare diseases, such as rare metabolic and hematology, and heredity angioedema, as well as plasma-derived therapies and vaccines. The company provides its products under the ENTYVIO, GATTEX/REVESTIVE, ALOFISEL, NATPARA, ADYNOVATE/ADYNOVI, TAKHZYRO, ELAPRASE, VPRIV, GAMMAGARD LIQUID/KIOVIG, HYQVIA, CUVITRU, ALBUMIN/FLEXBUMIN, NINLARO, and ALUNBRIG brands. It operates in Japan, the United States, Europe and Canada, Russia/CIS, Latin America, rest of Asia, the Middle East, Oceania, and Africa. The company has licensing agreements with TESARO, Inc., Denali Therapeutics, and Wave Life Sciences Ltd; collaboration agreements with Rani Therapeutics LLC, Novimmune S.A., AB Biosciences Inc., Sosei Group Corporation, and LogicBio Therapeutics, Inc.; strategic collaboration with Prometheus Biosciences, Inc; a license and research agreement with The University of Texas MD Anderson Cancer Center; a research collaboration agreements with Enzyre BV and Cerevance; a collaboration agreement with Artisan Bio, Inc.; and a multi-target rare disease collaboration with Evox Therapeutics Ltd., as well as licensing agreement with ProThera Biologics Inc. It also has a strategic alliance with Egle Therapeutics SAS and Evotec SE; a strategic partnership with Neurocrine Biosciences, Inc.; Carmine Therapeutics and HemoShear Therapeutics, LLC; strategic collaboration with KSQ Therapeutics to research, develop, and commercialize immune-based therapies for cancer; and strategic collaboration with Anima Biotech. Takeda Pharmaceutical Company Limited was founded in 1781 and is headquartered in Tokyo, Japan.

Read More
    Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
    Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.